Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice

Epilepsy and Behavior

Volumn 18, Issue 3, 2010, Pages 171-178

  Ghasemi, Mehdi ^a   Shafaroodi, Hamed ^b   Nazarbeiki, Saeed ^c   Meskar, Hossein ^c   Heydarpour, Pouria ^a   Ghasemi, Abbas ^a,d   Talab, Saman Shafaat ^a   Ziai, Pouya ^a   Bahremand, Arash ^a   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c SHAHED UNIVERSITY   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Calcium channel blockers; Clonic seizure; Lithium; Mice; N methyl D aspartate (NMDA) receptor; NMDA receptor antagonists; Pentylenetetrazole; Seizure

Indexed keywords

CALCIUM CHANNEL; DILTIAZEM; DIZOCILPINE; KETAMINE; LITHIUM CHLORIDE; NIFEDIPINE; PENTETRAZOLE; VERAPAMIL; AMINO ACID RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CALCIUM SIGNALING; CLONIC SEIZURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; SEIZURE THRESHOLD; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; SEIZURES;

ANALYSIS OF VARIANCE; ANIMALS; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EXCITATORY AMINO ACID ANTAGONISTS; LITHIUM CHLORIDE; MALE; MICE; PENTYLENETETRAZOLE; SEIZURES;

EID: 77954386109     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2010.04.002     Document Type: Article

References (111)

1. Nonaka S., Chuang D.M. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. NeuroReport 1998, 9:2081-2084.
2. Manji H.K., Moore G.J., Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?. Biol Psychiatry 1999, 46:929-940.
3. Minabe Y., Emori K., Kurachi M. Effects of chronic lithium treatment on limbic seizure generation in the cat. Psychopharmacology (Berl) 1988, 96:391-394.
4. Roy U., Mukherjee B.P. Correlation of lithium effect on electroshock-induced seizure in rats with its concentration in brain and plasma. Arch Int Pharmacodyn Thér 1982, 255:81-88.
5. Branchey M.H., Cavazos L.A., Cooper T.B. Effects of lithium on seizure susceptibility in alcoholized and non-alcoholized rats. Commun Psychopharmacol 1977, 1:213-224.
6. Honar H., Riazi K., Homayoun H., et al. Lithium inhibits the modulatory effects of morphine on susceptibility to pentylenetetrazole-induced clonic seizure in mice: involvement of a nitric oxide pathway. Brain Res 2004, 1029:48-55.
7. Kadlimatti S.H., Joseph T. Influence of lithium on the anticonvulsant activity of carbamazepine. Indian J Physiol Pharmacol 1987, 31:35-41.
8. Erwin C.W., Gerber C.J., Morrison S.D., James J.F. Lithium carbonate and convulsive disorders. Arch Gen Psychiatry 1973, 28:646-648.
9. Jus A., Villeneuve A., Gautier J., et al. Some remarks on the influence of lithium carbonate on patients with temporal epilepsy. Int J Clin Pharmacol 1973, 7:67-74.
10. Jus A., Villeneuve A., Gautier J., et al. Influence of lithium carbonate on patients with temporal epilepsy. Can Psychiatr Assoc J 1973, 18:77-78.
11. Schmidt J. Lithium suppresses seizure susceptibility in pentylenetetrazol-kindled rats. Biomed Biochim Acta 1986, 45:1167-1172.
12. Drummond A.H. Lithium and inositol lipid-linked signaling mechanisms. Trends Pharmacol Sci 1987, 8:129-133.
13. Williams R.S.B., Harwood A.J. Lithium therapy and signal transduction. Trends Pharmacol Sci 2000, 21:61-64.
14. 2+ levels. J Psychiatry Neurosci 2003, 28:115-125.
15. 2+ in single chromaffin cells. Eur J Pharmacol 1996, 306:219-226.
16. i mobilization. Gen Pharmacol 1995, 26:1659-1667.
17. Terao T. Calcium, lithium, and circadian rhythms. Biol Psychiatry 1992, 32:105-106.
18. 2+ influx and catecholamine secretion after lithium withdrawal. Neuropharmacology 2009, 57:311-321.
19. Sheng J.Z., Wong N.S., Tai K.K., Wong T.M. Lithium attenuates the effects of dynorphin A(1-13) on inositol 1, 4, 5-trisphosphate and intracellular Ca2+ in rat ventricular myocytes. Life Sci 1996, 59:2181-2186.
20. 2+ response in neutrophils from patients under chronic lithium therapy. Eur Arch Psychiatry Clin Neurosci 1994, 243:240-243.
21. 2+ response in neutrophils of manic-depressive patients: effect of lithium therapy. Neuropsychobiology 1993, 27:180-183.
22. Hiroi T., Wei H., Hough C., Leeds P., Chuang D.M. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J 2005, 5:102-111.
23. Sourial-Bassillious N., Rydelius P.-A., Aperia A., Aizman O. Glutamate-mediated calcium signaling: a potential target for lithium action. Neuroscience 2009, 161:1126-1134.
24. Yanagita T., Maruta T., Uezono Y., et al. Lithium inhibits function of voltage-dependent sodium channels and catecholamine secretion independent of glycogen synthase kinase-3 in adrenal chromaffin cells. Neuropharmacology 2007, 53:881-889.
25. Basselin M., Chang L., Bell J.M., Rapoport S.I. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 2006, 31:1659-1674.
26. 2+ channel. Epilepsia 2006, 47:839-850.
27. Schwartzkroin P.A., Slawsky M. Probable calcium spikes in hippocampal neurons. Brain Res 1977, 135:157-161.
28. Wong R.K., Prince D.A. Participation of calcium spikes during intrinsic burst firing in hippocampal neurons. Brain Res 1978, 159:385-390.
29. DeLorenzo R.J., Freedman S.D. Calcium-dependent phosphorylation of synaptic vesicle proteins and its possible role in mediating neurotransmitter release and vesicle function. Biochem Biophys Res Commun 1977, 77:1036-1043.
30. DeLorenzo R.J., Freedman S.D. Possible role of calcium-dependent protein phosphorylation in mediating neurotransmitter release and anticonvulsant action. Epilepsia 1977, 18:357-365.
31. Heinemann U., Lux H.D., Gutnick M.J. Extracellular free calcium and potassium during paroxsmal activity in the cerebral cortex of the cat. Exp Brain Res 1977, 27:237-243.
32. DeLorenzo R.J. A molecular approach to the calcium signal in brain: relationship to synaptic modulation and seizure discharge. Adv Neurol 1986, 44:435-464.
33. Meyer F.B., Anderson R.E., Sundt T.M., Sharbrough F.W. Selective central nervous system calcium channel blockers: a new class of anticonvulsant agents. Mayo Clin Proc 1986, 61:239-247.
34. Overweg J., Ashton D., de Beukelaar F., Binnie C.D., Wauquier A., van Wieringen A. Add-on therapy in epilepsy with calcium entry blockers. Eur Neurol 1986, 25(Suppl. 1):93-101.
35. Morales-Garcia J.A., Luna-Medina R., Martinez A., Santos A., Perez-Castillo A. Anticonvulsant and neuroprotective effects of the novel calcium antagonist NP04634 on kainic acid-induced seizures in rats. J Neurosci Res 2009, 87:3687-3696.
36. Shitak R., Sahai A.K., Hota D., Chakrabarti A. Anti-seizure efficacy of nimodipine in pentylenetetrazole and kainic acid combined seizure models in mice. Indian J Physiol Pharmacol 2006, 50:265-272.
37. Shitak R., Sahai A.K., Hota D., Chakrabarti A. Evaluation of the modulatory role of nimodipine in seizures induced by kainic acid and pentylenetetrazole in mice. Meth Find Exp Clin Pharmacol 2007, 29:11-17.
38. Navidpour L., Shafaroodi H., Miri R., Dehpour A.R., Shafiee A. Lipophilic 4-imidazoly-1, 4-dihydropyridines: synthesis, calcium channel antagonist activity and protection against pentylenetetrazole-induced seizure. Farmaco 2004, 59:261-269.
39. El-Abhar H.S., El Gawad H.M. Modulation of cortical nitric oxide synthase, glutamate, and redox state by nifedipine and taurine in PTZ-kindled mice. Epilepsia 2003, 44:276-281.
40. De Falco F.A., Bartiromo U., Majello L., Di Geronimo G., Mundo P. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992, 33:343-345.
41. Kamiński R.M., Mazurek M., Turski W.A., Kleinrok Z., Czuczwar S.J. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures. Pharmacol Biochem Behav 2001, 68:661-668.
42. Russo E., Constanti A., Ferreri G., Citraro R., De Sarro G. Nifedipine affects the anticonvulsant activity of topiramate in various animal models of epilepsy. Neuropharmacology 2004, 46:865-878.
43. Mandhane S.N., Aavula K., Rajamannar T. Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 2007, 16:636-644.
44. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs: III. Pentylenetetrazole seizure models. Epilepsy Res 1991, 8:171-189.
45. Eells J.B., Clough R.W., Browning R.A., Jobe P.C. Comparative fos immunoreactivity in the brain after forebrain, brainstem, or combined seizures induced by electroshock, pentylenetetrazol, focally induced and audiogenic seizures in rats. Neuroscience 2004, 123:279-292.
46. Sarkisian M.R. Overview of the current animal models for human seizure and epileptic disorders. Epilepsy Behav 2001, 2:201-216.
47. Folbergrová J. Anticonvulsant action of both NMDA and non-NMDA receptor antagonists against seizures induced by homocysteine in immature rats. Exp Neurol 1997, 145:442-450.
48. Ghasemi M., Raza M., Dehpour A.R. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol 2010, 24:585-594.
49. Shafaroodi H., Ghasemi M., Dehpour A.R. Elevation of pentylenetetrazole-induced seizure threshold in cholestatic mice: interaction between opioid and cannabinoid systems. J Gastroenterol Hepatol 2008, 23:e251-e257.
50. Niaki S.E., Shafaroodi H., Ghasemi M., Shakiba B., Fakhimi A., Dehpour A.R. Mouth breathing increases the pentylenetetrazole-induced seizure threshold in mice: a role for ATP-sensitive potassium channels. Epilepsy Behav 2008, 13:284-289.
51. Ghasemi M., Shafaroodi H., Karimollah A.R., et al. ATP-sensitive potassium channels contribute to the time-dependent alteration in the pentylenetetrazole-induced seizure threshold in diabetic mice. Seizure 2010, 2010:53-58.
52. Lauretti G.R., Ahmad I., Pleuvry B.J. The activity of opioid analgesics in seizure models utilizing N-methyl-DL-aspartic acid, kainic acid, bicuculline and pentylenetetrazole. Neuropharmacology 1994, 33:155-160.
53. Osonoe K., Mori N., Suzuki K., Osonoe M. Antiepileptic effects of inhibitors of nitric oxide synthase examined in pentylenetetrazole-induced seizures in rats. Brain Res 1994, 663:338-340.
54. Bahremand A., Nasrabady S.E., Ziai P., et al. Involvement of nitric oxide-cGMP pathway in the anticonvulsant effects of lithium chloride on PTZ-induced seizure in mice. Epilepsy Res 2010, 89:295-302.
55. Redrobe J.P., Bourin M. Evidence of the activity of lithium on 5-HT1B receptors in the mouse forced swimming test: comparison with carbamazepine and sodium valproate. Psychopharmacology (Berl) 1999, 141:370-377.
56. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol 2008, 18:323-332.
57. Minabe Y., Tanii Y., Tsunoda M., Kurachi M. Acute effect of TRH, flunarizine, lithium and zotepine on amygdaloid kindled seizures induced with low-frequency stimulation. Jpn J Psychiatry Neurol 1987, 41:685-691.
58. Minegishi A., Fukumori R., Satoh T., Kitagawa H. Effect of disulfiram in combination with L-tryptophan and lithium on pentylenetetrazol-induced seizure. Psychopharmacology (Berl) 1982, 77:289-291.
59. Shukla S., Mukherjee S., Decina P. Lithium in the treatment of bipolar disorders associated with epilepsy: an open study. J Clin Psychopharmacol 1988, 8:201-204.
60. Post R.M., Weiss S.R., Pert A. Differential effects of carbamazepine and lithium on sensitization and kindling. Prog Neuropsychopharmacol Biol Psychiatry 1984, 8:425-434.
61. Clifford D.B., Podolsky A., Zorumski C.F. Acute effects of lithium on hippocampal kindled seizures. Epilepsia 1985, 26:689-692.
62. Clifford D.B., Olney J.W., Maniotis A., Collins R.C., Zorumski C.F. The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience 1987, 23:953-968.
63. Popovic J., Krsljak E., Grbovic L., Stojic D. The effects of acute and chronic lithium treatment on rat submandibular salivation. Oral Dis 2005, 11:100-103.
64. Kirkby R.D., Carroll D.M., Grossman A.B., Subramanian S. Factors determining proconvulsant and anticonvulsant effects of inhibitors of nitric oxide synthase in rodents. Epilepsy Res 1996, 24:91-100.
65. Tsakiridou E., Bertollini L., de Curtis M., Avanzini G., Pape H.C. Selective increase in T-type calcium conductance of reticular thalamic neurons in a rat model of absence epilepsy. J Neurosci 1995, 15:3110-3117.
66. Vreugdenhil M., Wadman W.J. Enhancement of calcium currents in rat hippocampal CA1 neurons induced by kindling epileptogenesis. Neuroscience 1992, 49:373-381.
67. Wasterlain C.G., Fujikawa D.G., Penix L., Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993, 34(Suppl. 1):S37-S53.
68. Sohn R.S., Ferrendelli J.A. Anticonvulsant drug mechanisms: phenytoin, phenobarbital, and ethosuximide and calcium flux in isolated presynaptic endings. Arch Neurol 1976, 33:626-629.
69. 2+ uptake and amino acid neurotransmitter release in vitro. Epilepsia 1987, 28:378-382.
70. Meyer F.B. Calcium, neuronal hyperexcitability and ischemic injury. Brain Res Brain Res Rev 1989, 14:227-243.
71. Goldensohn E.S., Purpura D.P. Intracellular potentials of cortical neurons during focal epileptogenic discharges. Science 1963, 139:840-842.
72. Wong R.K., Prince D.A. Dendritic mechanisms underlying penicillin-induced epileptiform activity. Science 1979, 204:1228-1231.
73. Amano H., Amano T., Matsubayashi H., Ishihara K., Serikawa T., Sasa M. Enhanced calcium influx in hippocampal CA3 neurons of spontaneously epileptic rats. Epilepsia 2001, 42:345-350.
74. Bingmann D., Speckmann E.J. Specific suppression of pentylenetetrazol-induced epileptiform discharges in CA3 neurons (hippocampal slice, guinea pig) by the organic calcium antagonists flunarizine and verapamil. Exp Brain Res 1989, 74:239-248.
75. Witte O.W., Speckmann E.J., Walden J. Motor cortical epileptic foci in vivo: actions of a calcium channel blocker on paroxysmal neuronal depolarizations. Electroencephalogr Clin Neurophysiol 1987, 66:43-55.
76. Walden J., Pockberger H., Speckmann E.J., Petsche H. Paroxysmal neuronal depolarizations in the rat motorcortex in vivo: intracellular injection of the calcium agonist BAY K 8644. Exp Brain Res 1986, 64:607-609.
77. Bolger G.T., Weissman B.A., Skolnick P. The behavioral effects of the calcium agonist Bay K 8644 in the mouse: antagonism by the calcium antagonist nifedipine. Naunyn-Schmiedebergs Arch Pharmacol 1985, 328:373-377.
78. De Sarro G.B., Meldrum B.S., Nistico G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 1988, 93:247-256.
79. Ashton D., Wauquier A. Effects of some anti-epileptic, neuroleptic and GABAminergic drugs on convulsions induced by D, L-allylglycine. Pharmacol Biochem Behav 1979, 11:221-226.
80. Desmedt L.K., Niemegeers C.J., Janssen P.A. Anticonvulsive properties of cinnarizine and flunarizine in rats and mice. Arzneimittelforschung 1975, 25:1408-1413.
81. 2+ antagonist. Epilepsia 1987, 28:409-414.
82. Walden J., Speckmann E.J. Suppression of recurrent generalized tonic-clonic seizure discharges by intraventricular perfusion of a calcium antagonist. Electroencephalogr Clin Neurophysiol 1988, 69:353-362.
83. Waxman E.A., Lynch D.R. N-Methyl-D-aspartate receptor subtypes: multiple roles in excitotoxicity and neurological disease. Neuroscientist 2005, 11:37-49.
84. Kalia L.V., Kalia S.K., Salter M.W. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008, 7:742-755.
85. Thomas R.J. Excitatory amino acids in health and disease. J Am Geriatr Soc 1995, 43:1279-1289.
86. Ahmed M.M., Arif M., Chikuma T., Kato T. Pentylenetetrazol-induced seizures affect the levels of prolyl oligopeptidase, thimet oligopeptidase and glial proteins in rat brain regions, and attenuation by MK-801 pretreatment. Neurochem Int 2005, 47:248-259.
87. Croucher M.J., Collins J.F., Meldrum B.S. Anticonvulsant action of excitatory amino acid antagonists. Science 1982, 216:899-901.
88. Gmiro V.E., Serdyuk S.E. Combined blockade of AMPA and NMDA receptors in the brain of rats prevents pentylenetetrazole-induced clonic and tonic-clonic seizures without ataxia. Bull Exp Biol Med 2008, 145:728-730.
89. Mareš P., Mikulecka A. Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav 2009, 14:32-39.
90. Velisek L., Veliskova J., Ptachewich Y., Shinnar S., Moshe S.L. Effects of MK-801 and phenytoin on flurothyl-induced seizures during development. Epilepsia 1995, 36:179-185.
91. Jones A.W., Croucher M.J., Meldrum B.S., Watkins J.C. Suppression of audiogenic seizures in DBA/2 mice by two new dipeptide NMDA receptor antagonists. Neurosci Lett 1984, 45:157-161.
92. Hironaka N., Niki H. Effects of N-methyl-D-aspartate receptor subunit antagonists on regulation of susceptibility to audiogenic seizures in rats. Neurosci Lett 2000, 288:139-142.
93. Borris D.J., Bertram E.H., Kapur J. Ketamine controls prolonged status epilepticus. Epilepsy Res 2000, 42:117-122.
94. Dodson W.E. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993, 34:S18-S24.
95. Krystal A.D., Weiner R.D., Dean M.D., et al. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin Neurosci 2003, 15:27-34.
96. Kleckner N.W., Glazewski J.C., Chen C.C., Moscrip T.D. Subtypeselective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999, 289:886-894.
97. Sachdeo R., Kramer L.D., Rosenberg A., Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992, 32:386-392.
98. Leppik I.E., Dreifuss F.E., Pledger G.W., et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991, 41:1785-1789.
99. Faught E., Sachdeo R.C., Remler M.P., et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology 1993, 43:688-692.
100. Helman J., Kuyatt B.L., Takuma T., Seligmann B., Baum B.J. ATP-dependent calcium transport in rat parotid basolateral membrane vesicles: modulation by agents which elevate cyclic AMP. J Biol Chem 1986, 261:8919-8923.
101. Yamaji T., Kagaya A., Uchitomi Y., Yokota N., Yamawaki S. Chronic treatment with antidepressants, verapamil, or lithium inhibits the serotonin-induced intracellular calcium response in individual C6 rat glioma cells. Life Sci 1997, 60:817-823.
102. Nonaka S., Hough C.J., Chuang D.M. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998, 95:2642-2647.
103. Varney M.A., Godfrey P.P., Drummond A.H., Watson S.P. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH3 pituitary cells. Mol Pharmacol 1992, 42:671-678.
104. 2+ mobilization in the rat hippocampal slices. Neurochem Int 1995, 26:233-238.
105. Wasserman M.J., Corson T.W., Sibony D., et al. Chronic lithium treatment attenuates intracellular calcium mobilization. Neuropsychopharmacology 2004, 29:759-769.
106. Hashimoto R., Hough C., Nakazawa T., Yamamoto T., Chuang D.M. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002, 80:589-597.
107. Chuang D.-M., Chen R.-W., Chalecka-Franaszek E., et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 2002, 4:129-136.
108. Ma J., Zhang G.Y. Lithium reduced N-methyl-D-aspartate receptor subunit 2A tyrosine phosphorylation and its interactions with Src and Fyn mediated by PSD-95 in rat hippocampus following cerebral ischemia. Neurosci Lett 2003, 348:185-189.
109. Ma J., Zhang G.Y., Liu Y., Yan J.Z., Hao Z.B. Lithium suppressed Tyr-402 phosphorylation of proline-rich tyrosine kinase (Pyk2) and interactions of Pyk2 and PSD-95 with NR2A in rat hippocampus following cerebral ischemia. Neurosci Res 2004, 49:357-362.
110. O'Neill S.K., Bolger G.T. Anticonvulsant activity of MK-801 and nimodipine alone and in combination against pentylenetetrazole and strychnine. Pharmacol Biochem Behav 1989, 32:595-600.
111. Palmer G.C., Stagnitto M.L., Ray R.K., Knowles M.A., Harvey R., Garske G.E. Anticonvulsant properties of calcium channel blockers in mice: N-methyl-D, L-aspartate- and Bay K 8644-induced convulsions are potently blocked by the dihydropyridines. Epilepsia 1993, 34:372-380.